Circulating IL‐6 and sIL‐6R in Patients with Hepatocellular Carcinoma
- 1 June 2002
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 963 (1), 46-52
- https://doi.org/10.1111/j.1749-6632.2002.tb04093.x
Abstract
Interleukin-6 plays a central role in regulating the immune system, hematopoiesis, and acute phase reaction. It interacts with a receptor complex consisting of a specific ligand-binding protein (IL-6R, gp80) and a signal transduction protein (gp130). In this report, serum levels of IL-6 and a soluble form of the interleukin-6 receptor (sIL-6R) were evaluated in patients with hepatocellular carcinoma. The correlation between IL-6 and sIL-6R values, the stage of hepatocellular carcinoma, and main liver function tests was also studied.This publication has 14 references indexed in Scilit:
- The soluble interleukin 6 receptor: mechanisms of production and implications in diseaseThe FASEB Journal, 2000
- Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinomaCancer, 1999
- Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myelomaBritish Journal of Haematology, 1999
- Marked Elevation of Serum Interleukin-6 in Patients With CholangiocarcinomaAnnals of Surgery, 1998
- Interleukin 6 and its Receptor: Ten Years LaterInternational Reviews of Immunology, 1998
- Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virusThe Esophagus, 1997
- Serum levels of interleukin 6 in patients with lung cancerBritish Journal of Cancer, 1995
- Soluble receptors for cytokines and growth factors: generation and biological functionBiochemical Journal, 1994
- Interleukin-6 in Renal Cell CarcinomaJournal of Urology, 1992
- Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1991